Bronchial Asthma
Pipeline by Development Stage
Respiratory is a $39.4B mature market dominated by established inhalers and combination therapies with significant patent cliff risk.
Key Trends
- Consolidation around GSK's triple-therapy franchises (Trelegy, Breo, Anoro)
- Major patent expirations 2026-2031 creating $7.8B revenue cliff
- High clinical trial activity (4,862 trials) suggesting pipeline innovation despite market maturity
Career Verdict
Respiratory offers stable commercial careers but limited growth upside; best for professionals seeking established markets with strong commercial infrastructure rather than innovation-driven advancement.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 46% | Launch | Growing | 15.0yr |
| 2 | TRULICITY (dulaglutide) | Eli Lilly and Company | $7.4B | 19% | Peak | Stable | |
| 3 | TRELEGY ELLIPTA (fluticasone/umeclidinium/vilanterol) | GSK | $4.5B | 11% | Peak | Declining | 4.9yr |
| 4 | CREON (pancrelipase) | AbbVie | $1.5B | 4% | Approaching LOE | Declining | |
| 5 | BREO ELLIPTA (fluticasone/vilanterol) | GSK | $1.4B | 4% | Peak | Declining | 4.9yr |
Drug Class Breakdown
dominant market driver
fragmented portfolio
rapidly expanding
legacy product
patent cliff approaching
mature maintenance therapy
Career Outlook
StableRespiratory is a stable, mature market suitable for commercial and medical affairs professionals seeking established career paths, but offers limited growth or innovation-focused opportunities. The impending patent cliff ($7.8B+ revenue at risk 2026-2031) will drive near-term restructuring and consolidation, potentially reducing headcount in 2027-2028. Professionals should expect strong compensation in Medical Affairs and field roles but limited advancement into strategic or R&D positions.
Breaking In
New graduates should prioritize commercial, field-based, or Medical Affairs roles over R&D; respiratory offers structured training and stable compensation but limited innovation exposure, so pair this experience with cross-therapeutic skill-building for long-term mobility.
For Experienced Professionals
Experienced professionals should evaluate whether to maximize earnings in this mature, stable market or transition to higher-growth areas (oncology, cell therapy); respiratory consolidation 2027-2030 will reduce senior-level opportunities, so consider strategic moves before patent cliff impacts headcount.
In-Demand Skills
Best For
Hiring Landscape
The respiratory sector shows modest hiring momentum (510 jobs across tracked positions) concentrated in commercial and engineering roles, with AstraZeneca and GSK leading. Medical Affairs positions command premium salaries ($314K avg) but represent only 3% of openings, reflecting the mature market's focus on sales execution over innovation. Hiring velocity is moderate and reflects market consolidation rather than expansion, suggesting limited career progression opportunities for early-to-mid career professionals.
Top Hiring Companies
By Department
Respiratory hiring favors commercial and field-based roles over R&D; Medical Affairs roles offer premium compensation but are scarce, making this area competitive for specialized talent.
On Market (4)
Approved therapies currently available
Competitive Landscape
12 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 25 trials with date data
Clinical Trials (25)
Total enrollment: 18,514 patients across 25 trials
Effects of Montelukast in Asthmatic Children With and Without Food Allergy
BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma
Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation
Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH
BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients
Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma
Effect of High Dose Ciclesonide on Asthma Control
Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma
Symbicort Rapihaler Therapeutic Equivalence Study
Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma
Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-
Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)
EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI
Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)
Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)
Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects
A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma
Fasenra Pediatric Japan Post-Marketing Study(PMS)
Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation
Symbicort Turbuhaler 30/60 Clinical Experience Investigation
Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation
A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice
A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART
Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation
Related Jobs in Respiratory
(Bio-)Chemiker Analytik, M.Sc. (w/m/d)
Compliance Director
Medical Device Sales Associate Territory Account Manager
Sr. HR Operations Specialist
Medical Device Sales Territory Account Manager
Peripheral Territory Manager East Poland (m/f/d)
Phase Legend
Key Insights
Related Indications
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.